The Kenya BioVax Institute Limited’s mandate is to manufacture, package and commercialize specialized health products and technologies including vaccines, therapeutics and other biomedical products under the following objects, including but not limited to:
Biovax will carry out research and develop a wide range of products as outlined below;
COVID-19 vaccine (single dose), viral vector based vaccine
COVID-19 ( 2-dose), viral vector based vaccine
COVID-19 (2 dose), mRNA-based vaccine
Anticancer agents, including monoclonal antibodies
Gene therapies
Antisera, including Tetanus antitoxin and anti-rabies serum
Insulins
Kenya BioVax will carry out research and collaborate through various research programs with research institutions, universities, and strategic partners to design and develop new technologies and clinical platforms for vaccines. We are keen to engage with manufacturing companies to establish technology transfer arrangements and further support centres of research in technology transfer and commercialisation of research outputs. Our support will aim to reach local and regional pharmaceutical industries in development and production of quality and affordable products.
